dpp 4 inhibitors vs glp 1 agonist GLP-1 receptor versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Working mechanisms of GLP-1, GLP-1
Description
TFEB, transcription factor EB
GLP-1R, glucagon-like peptide-1 receptor
Pancreatitis Acute pancreatitis has occurred in patients treated with GLP-1 agonists, including tirzepatide
Biological concern for PDAC based on preclinical studies In 2005, exenatide, the first GLP-1RA was marketed as treatment for T2D
Why Are GLP-1 and Peptide Therapies Becoming Popular
